Related Experiment Videos
BU98008, a highly selective imidazoline(1)-receptor ligand
E S J Robinson1, R E Price, D J Nutt
1Psychopharmacology Unit, School of Medical Sciences, Bristol BS8 1TD, UK.
Annals of the New York Academy of Sciences
|March 19, 2004
Summary
The novel compound BU98008, an isoquinoline derivative, shows high affinity for the I(1) receptor. Initial studies suggest it may act as an I(1) receptor antagonist, but further central administration studies are needed.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Neuroscience
Background:
- The imidazoline I(1) receptor is a potential target for cardiovascular regulation.
- Novel ligands are needed to selectively target I(1) receptors for therapeutic development.
Purpose of the Study:
- To characterize the binding profile and in vivo effects of BU98008, a novel isoquinoline derivative.
- To evaluate BU98008's potential as an I(1) receptor antagonist.
Main Methods:
- Radioligand binding assays were performed using rat kidney and brain membranes.
- In vivo studies assessed the effect of peripheral BU98008 administration on blood pressure in rats.
Main Results:
- BU98008 exhibited high affinity for the I(1) receptor in rat kidney membranes.
- The compound showed low affinity for I(2) binding sites and alpha(2)-adrenoceptors.
- Peripheral administration of BU98008 did not alter blood pressure.
Conclusions:
- BU98008 is a selective ligand for the I(1) receptor.
- Preliminary data suggest BU98008 may function as an I(1) receptor antagonist.
- Further investigation involving central administration is required to fully assess its potential hypotensive effects.